Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer

Head Neck. 2010 May;32(5):646-55. doi: 10.1002/hed.21239.

Abstract

Background: The aim of this study was to evaluate the significance of nuclear factor-kappa B (NF-kappaB) expression as a marker of radioresistance in early-stage laryngeal cancer.

Methods: Thirty-five patients with local recurrence and 70 case-matched patients without local recurrence were entered in this study. NF-kappaB expression was compared with Bcl-2 and epidermal growth factor (EGF) receptor expression by immunohistochemistry, using pretreatment biopsy specimens. The prognostic value of NF-kappaB was also evaluated. Twenty-nine recurrent tumors were compared with pretreatment tumors.

Results: NF-kappaB expression in pretreatment tumors significantly correlated with local tumor control (p = .01), but bcl-2 and EGF receptor expression did not. Only NF-kappaB expression showed prognostic significance for local tumor control in both univariate and multivariate analyses (p = .008 and .04, respectively). NF-kappaB expression was markedly enhanced in 23 of 29 (80%) recurrent tumors.

Conclusion: NF-kappaB expression may be a novel marker of radioresistance in early-stage laryngeal cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy*
  • Case-Control Studies
  • ErbB Receptors / metabolism
  • Female
  • Humans
  • Immunohistochemistry
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • NF-kappa B / metabolism*
  • Neoplasm Recurrence, Local / metabolism
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Radiation Tolerance*

Substances

  • Biomarkers, Tumor
  • NF-kappa B
  • Proto-Oncogene Proteins c-bcl-2
  • ErbB Receptors